Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439485 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
A Phase 1 study of Advanced Cholangiocarcinoma and FGFR2 Fusion, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06439485: Recruiting Phase 1 study of Advanced Cholangiocarcinoma and FGFR2 Fusion, sponsored by M.D. Anderson Cancer Center.
NCT06439485 is a Phase 1 study of Advanced Cholangiocarcinoma and FGFR2 Fusion that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants, below the 114-participant average among 3 other Advanced Cholangiocarcinoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06439485, a Phase 1 study of Advanced Cholangiocarcinoma and FGFR2 Fusion, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Pemigatinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2030-02-22 |
| Phase | Phase 1 |
What NCT06439485 shows while recruiting
NCT06439485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 114-participant average among 3 other Advanced Cholangiocarcinoma trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Advanced Cholangiocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06439485 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06439485 about?
NCT06439485 is a clinical study titled "Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion". To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
What is the current status of trial NCT06439485?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-11-19. Estimated completion is 2030-02-22.
What conditions does trial NCT06439485 study?
This clinical trial studies the following conditions: Advanced Cholangiocarcinoma, FGFR2 Fusion.
What interventions are being tested in trial NCT06439485?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT06439485?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06439485 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
RECRUITING · Phase 2
-
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI